KYLE BECHAZ: Open Payments
NPI 1497042287 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$515 in 20 payments from 8 companies in 2025. Trend: 2023 $145 · 2024 $263 · 2025 $515
Food & beverage: $515
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $181 |
| GE HEALTHCARE | 5 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $60 |
| Lundbeck LLC | 2 | $54 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
Products named: VRAYLAR, REXULTI, CAPLYTA, Auvelity, TRINTELLIX, COBENFY.
Industry payments across CA — which companies pay providers there.
